NMD-GPS (Genomic and Proteomic Signatures as a GPS in Neuromuscular Diseases) is a multidisciplinary German/European project funded with 2,9 million Euros for a total period of three years (by the European Regional Development Fund; ERDF) and applying proteogenomics to improve NMD diagnostics by replacing immunology-based analyses with proteomics. In this project, NMD-causative-proteins are quantified by targeted proteomics, while untargeted proteomics on the same protein extracts then aims to map pathophysiological cascades across diseases, including both genetic and acquired NMDs. Intersection of proteogenomics and clinical data via machine learning will enable identification of molecular causes in an antibody-independent fashion as well as pinpointing significant protein co-regulations.
A newly developed method based on artificial intelligence is intended to optimize both the diagnosis and treatment of neuromuscular diseases. The Aachen-based optimization specialist, INFORM GmbH, is contributing the expertise of its DataLab to health research for the first time in a research project with the Neuropediatric Department of the University Hospital Essen, the Leibniz Institute for Analytical Sciences (ISAS) and the MVZ Institute for Clinical Genetics in Bonn. The aim is to improve the diagnosis and treatment of neuromuscular diseases by analyzing patient data using a special algorithm.
Generally, by addressing the need to
(i) replace the antibody-based immunological diagnostic analysis of muscle biopsy specimen derived from patients suffering from neuromuscular diseases (NMDs) as well as to
(ii) identify pathomechanisms common in different NMDs toward the definition of unified treatment concepts, NMD-GPS combines phenomics, genomics, proteomics and machine learning in an interdisciplinary manner.
Department of Neuropediatrics
(Prof. Dr. Ulrike Schara, Lead & Dr. Andreas Roos, Project Manager)
University Hospital Essen
For further question, please contact:
Dr. Andreas Roos (Project Manager)